Home News Alexion Pharmaceuticals to Establish Global Supply Chain and Quality Operations in Ireland
Alexion Pharmaceuticals to Establish Global Supply Chain and Quality Operations in Ireland

26/07/13

Alexion Pharmaceuticals is expanding its global presence with the opening of a new office and laboratory facility in Dublin in conjunction with the company’s decision to establish a global supply chain facility in Ireland.  Alexion has begun the process of recruiting approximately 50 employees by year-end for a range of initial positions in its supply chain, quality assurance, quality control and logistics functions by year-end.

Alexion’s new, additional global supply chain and quality staff in Ireland are expected to begin supplying Soliris® (eculizumab) to patients with PNH and aHUS, two severe and life-threatening ultra-rare disorders, by the end of 2013.  The company’s expanding Irish workforce will also manage the supply of additional Alexion medicines to patients following regulatory approvals for a series of anticipated launches of new therapies over the next several years.


“Ireland’s government and universities have an unparalleled commitment and robust partnerships with regard to education and training for pharmaceutical manufacturing, quality assurance, quality control and supply logistics.  For these reasons, as we continue to expand our global supply chain and quality team, we are very pleased to come to Ireland for its highly skilled and educated workforce,” said Stephen Squinto, PhD, Executive Vice President and Chief Global Operations Officer at Alexion.

 


Alexion Pharmaceuticals, Inc. is a global biopharmaceutical company focused on the development and delivery of therapies for severe and life-threatening diseases that are also ultra-rare. The addition of employees in Ireland is part of the on-going expansion in the company’s global organisation.

Alexion Pharmaceuticals, Inc. is a biopharmaceutical company focused on serving patients with severe and ultra-rare disorders through the innovation, development and commercialization of life-transforming therapeutic products. Alexion is the global leader in complement inhibition and has developed and markets a treatment for patients with PNH and aHUS, two debilitating, ultra-rare and life-threatening disorders caused by chronic uncontrolled complement activation.

Comments (0)Add Comment

Write comment
You must be logged in to post a comment. Please register if you do not have an account yet.

busy
 

Upcoming Events

No events found.